Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JATT JATT Acquisition	$1.59 +8.2%	$1.35	$7.80 ▼ $12.38	$27.43M	N/A	41,322 shs	390,775 shs
MYNZ Mainz Biomed	$1.69 -1.7%	$1.69	$1.30 ▼ $18.40	$7.87M	0.25	178,429 shs	130,134 shs
RNTX Rein Therapeutics	$1.16 -3.8%	$1.47	$1.04 ▼ $4.40	$27.66M	1.31	60,633 shs	32,234 shs
TENX Tenax Therapeutics	$5.95 +0.7%	$5.92	$3.25 ▼ $7.89	$24.52M	1.46	24,284 shs	37,399 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JATT JATT Acquisition	+4.26%	-6.37%	+12.21%	+25.64%	-55.32%
MYNZ Mainz Biomed	+17.01%	+17.01%	-7.03%	-24.23%	-87.71%
RNTX Rein Therapeutics	+1.69%	+3.90%	-20.00%	-49.15%	+119,999,900.00%
TENX Tenax Therapeutics	+0.34%	-3.27%	+0.17%	+3.68%	+46.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	2.6599 of 5 stars	3.3	3.0	0.0	0.0	2.5	0.8	1.3
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	1.9721 of 5 stars	3.6	1.0	0.0	0.0	3.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JATT JATT Acquisition	0.00	N/A	N/A	N/A
MYNZ Mainz Biomed	2.50	Moderate Buy	$14.00	728.40% Upside
RNTX Rein Therapeutics	0.00	N/A	N/A	N/A
TENX Tenax Therapeutics	3.25	Buy	$17.00	185.71% Upside

Current Analyst Ratings Breakdown

Latest MYNZ, JATT, RNTX, and TENX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/14/2025	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
5/15/2025	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JATT JATT Acquisition	N/A	N/A	$0.06 per share	27.08	($0.53) per share	N/A
MYNZ Mainz Biomed	$890K	8.70	N/A	N/A	$2.61 per share	0.65
RNTX Rein Therapeutics	N/A	N/A	$0.43 per share	2.68	$0.43 per share	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$26.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JATT JATT Acquisition	$6.85M	N/A	0.00	∞	N/A	N/A	-49.58%	2.84%	N/A
MYNZ Mainz Biomed	-$21.65M	-$65.60	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	-$62.88M	-$2.86	N/A	N/A	N/A	N/A	-86.07%	-31.11%	N/A
TENX Tenax Therapeutics	-$17.60M	-$0.92	N/A	N/A	N/A	N/A	-31.64%	-30.61%	N/A

Latest MYNZ, JATT, RNTX, and TENX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RNTX Rein Therapeutics	-$0.22	-$0.28	-$0.06	-$0.28	N/A	N/A
8/13/2025	Q2 2025	TENX Tenax Therapeutics	-$0.50	-$0.27	+$0.23	-$0.27	N/A	N/A
5/15/2025	Q1 2025	RNTX Rein Therapeutics	-$0.21	-$0.25	-$0.04	-$0.25	N/A	N/A
5/14/2025	Q1 2025	TENX Tenax Therapeutics	-$0.48	-$0.28	+$0.20	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JATT JATT Acquisition	N/A	0.15	0.15
MYNZ Mainz Biomed	0.14	1.32	1.26
RNTX Rein Therapeutics	N/A	1.39	1.39
TENX Tenax Therapeutics	N/A	40.48	40.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JATT JATT Acquisition	47.97%
MYNZ Mainz Biomed	N/A
RNTX Rein Therapeutics	90.89%
TENX Tenax Therapeutics	1.67%

Insider Ownership

Company	Insider Ownership
JATT JATT Acquisition	20.00%
MYNZ Mainz Biomed	18.20%
RNTX Rein Therapeutics	5.10%
TENX Tenax Therapeutics	3.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JATT JATT Acquisition	3	17.25 million	13.80 million	Not Optionable
MYNZ Mainz Biomed	30	4.58 million	3.75 million	Not Optionable
RNTX Rein Therapeutics	9	23.05 million	21.87 million	N/A
TENX Tenax Therapeutics	9	4.15 million	4.02 million	Not Optionable

MYNZ, JATT, RNTX, and TENX Headlines

Recent News About These Companies

Tenax Posts Wider Loss in Fiscal Q2

August 14 at 5:50 AM | aol.comA

Tenax Therapeutics reports Q2 EPS (27c), consensus (45c)

August 14 at 5:50 AM | msn.com

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13 at 4:19 PM | globenewswire.com

Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Tuesday

August 10, 2025 | americanbankingnews.com

TENX Tenax Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | globenewswire.com

Tenax Therapeutics Inc.

May 9, 2025 | barrons.com

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts

April 16, 2025 | seekingalpha.com

Tenax Therapeutics files to sell 4.14M shares of common stock for holders

April 16, 2025 | markets.businessinsider.com

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025 | globenewswire.com

Tenax Therapeutics reports Q4 EPS (18c), consensus (43c)

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics (TENX) Gets a Buy from William Blair

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics: Q4 Earnings Snapshot

March 25, 2025 | timesunion.comT

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 25, 2025 | globenewswire.com

Tenax Therapeutics Inc TENX

March 14, 2025 | morningstar.comM

Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)

March 6, 2025 | markets.businessinsider.com

Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103

March 5, 2025 | markets.businessinsider.com

Tenax Therapeutics prices 378,346 shares at $6.04 in private placement

March 5, 2025 | markets.businessinsider.com

Tenax Therapeutics Announces $25 Million Private Placement

March 5, 2025 | globenewswire.com

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

March 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ, JATT, RNTX, and TENX Company Descriptions

JATT Acquisition NYSE:JATT

$1.59 +0.12 (+8.16%)

As of 08/13/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

Mainz Biomed NASDAQ:MYNZ

$1.69 -0.03 (-1.74%)

Closing price 04:00 PM Eastern

Extended Trading

$1.66 -0.03 (-2.07%)

As of 07:38 PM Eastern

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

Rein Therapeutics NASDAQ:RNTX

$1.16 -0.05 (-3.75%)

As of 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Tenax Therapeutics NASDAQ:TENX

$5.95 +0.04 (+0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$5.95 0.00 (0.00%)

As of 06:33 PM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time